Contact a Bextra Lawyer
April 6th, 2007
"Bextra Suit Filed"
Bextra , the popular cox-2 inhibitor recalled by Pfizer, is the subject of another lawsuit.
Rita Fohne has filed her lawsuit against Pfizer in Madison County, Illinois, seeking compensation for the personal injury and economic damages she allegedly sustained as a result of the use of the drug.
The drug caused her to suffer a heart attack and other cardiovascular injuries, according to the suit filed by Fohne's lawyers Robert Rowland and Aaron Dickey.
According to the suit, Fohne was taking Bextra for six months or more before she had the heart attack.
History of Bextra
After its FDA approval in 2001, Bextra was popularly taken to treat the symptoms of rheumatoid arthritis and osteoarthritis.
However, in 2005, the FDA asked Pfizer to halt sales of Bextra in the United States because it was linked with adverse health events.
The Lawsuit
According to the suit, the drug was defective and unreasonably dangerous at the time it was sold to Fohne, and it subjected her to an increased risk of heart attack, stroke, and other cardiovascular health risks that exceeded the drug's benefits when there were safe alternatives available.
The suit also claims that Pfizer did not adequately test and study Bextra before releasing it or marketing it, or that it ignored data that allegedly showed that the drug was dangerous.
Furthermore, the suit claims that the drug came with inadequate warnings of the drug's dangers.
The suit also claims that Pfizer knew of the dangers the product posed to its users, but continued to manufacture, market, distribute and sell it simply to maximize profits without regard for the health of the public.
Fohne seeks damages in excess of $250,000 plus attorneys' fees and other relief the court may deem appropriate.
Harmed by Bextra? Please contact us today for a complimentary consultation with an experienced defective drug attorney who can help you plan the best way to recover compensation for your past and future medical expenses, pain, suffering and more.